TrumpRx.gov launches with Zepbound and Mounjaro listings

The federal government's most-favored-nation drug pricing website, TrumpRx.gov, launched on February 5, 2026, and now lists cash-pay prices for GLP-1 medications, including Eli Lilly's tirzepatide products Zepbound and Mounjaro ^[3][4]. The site does not sell drugs itself. It displays a price and then routes shoppers to the manufacturer's direct-to-consumer channel ^[1][2].

The Zepbound vial listing shows an original price of $1,087.00, savings of $788.00, and a TrumpRx price of $299.00, which the page describes as up to 72% off ^[1]. The Mounjaro single-dose pen listing shows an original price of $1,112.16, savings of $613.16, and a final price of $499.00, labeled 55% off ^[2]. Both pages let shoppers pick a strength: 2.5, 5, 7.5, 10, 12.5 or 15 mg for the Zepbound vial, and the equivalent mg/0.5 mL strengths for the Mounjaro pen ^[1][2].

What the listings actually say

Both pages state plainly that these are out-of-pocket prices and add: "If you have insurance, check your co-pay first—it may be even lower" ^[1][2]. Both also carry an asterisk noting that eligibility is required and terms and conditions apply, with links to Lilly's self-pay terms ^[1][2].

Orders are not processed by the government. The Zepbound page says Eli Lilly "manages all Zepbound (Tirzepatide) Vial orders through LillyDirect," which handles eligibility confirmation and delivery ^[1]. The Mounjaro page says LillyDirect "will guide you through savings options and offers delivery" ^[2]. Both list LillyDirect Customer Care at 844-559-3471, 9 a.m. to 7 p.m. ET, Monday through Friday ^[1][2].

The TrumpRx home page frames the effort as most-favored-nation pricing and claims more than $700,000,000 saved for Americans ^[4]. Its featured comparison grid lists the Wegovy Pill at $149 a month versus $1,349, the Wegovy Pen at $199 versus $1,349, Ozempic at $199 versus $1,028, and Zepbound at $299 versus $1,087 ^[4]. Wegovy, Ozempic and the oral semaglutide pill are all semaglutide from Novo Nordisk; Zepbound and Mounjaro are tirzepatide from Lilly ^[1][2][4].

One caveat: the sources do not fully agree on whether a single flat price applies to every strength. The TrumpRx home page shows Zepbound as a flat $299 per month ^[4], while a March 2026 Pharmacy Times commentary described TrumpRx monthly costs as $149 to $299 for semaglutide tablets, $199 to $349 for semaglutide injections, and $299 to $449 for tirzepatide injections ^[3]. The Zepbound product page lists a "Fill period" of "N/a" and says "Last updated unavailable," so how often the listed price changes is not stated ^[1].

Why it matters for patients

For people paying cash, the listings give a single public reference number for what these drugs cost without insurance, and the gap between the listed original price and the final price is large — $788.00 on the Zepbound vial and $613.16 on the Mounjaro pen ^[1][2]. That matters because cash prices for GLP-1s have been a moving target and hard to compare.

But the fine print shapes who actually gets those prices. Eligibility rules apply, the terms are Lilly's, and the transaction happens on LillyDirect rather than at a local pharmacy counter ^[1][2]. The sites themselves flag that an insurance copay could be lower than the cash price ^[1][2]. What the sources do not spell out is who qualifies, whether the price changes by dose or over time, or how pharmacies that are not part of the manufacturer channel fit in.

What happens next

The launch landed in the middle of a federal crackdown on compounded GLP-1s. On February 5, 2026, Hims & Hers announced a commercial launch of a compounded semaglutide pill ^[3]. On February 6, the FDA said it would move to restrict GLP-1 active ingredients used in non-FDA-approved compounded products and warned that failure to fix violations "may result in legal action without further notice, including, without limitation, seizure and injunction" ^[3]. On February 9, Novo Nordisk sued Hims & Hers over its compounded semaglutide ^[3]. An FDA warning letter to compounder Boothwyn Pharmacy, dated January 16, was published February 10 ^[3].